Clinical case of primary generalized amyloidiosis

Natalia A. Cherkasova , Irina S. Komarova , Nadezhda V. Mukhina , Nikita V. Dyatlov

For citation:

Abstract

The article describes the clinical case of primary amyloidosis (AL type) with predominant heart and kidney damage complicated by the development of multiple organ dysfunction syndrome in a 56-year-old woman.

Keywords: clinical case, systemic AL-amyloidosis, restrictive cardiomyopathy, heart failure

References

1. Демко И.В., Пелиновская Л.И., Соловьева И.А. и др. Первичный амилоидоз сердца. Клиническая медицина. 2017; 95 (11): 971–6. DOI: 10.18821/0023-2149-2017-95-11-971-976 [Demko I.V., Pelinovskaya L.I., Soloveva Irina A. et al. Primary cardiac amyloidosis. Klinicheskaya Meditsina/Clinical Medicine. 2017; 95 (11): 971–6. DOI: 10.18821/0023-2149-2017-95-11-971-976 (in Russian).]

2. Драганова А.С., Соболева А.В., Эртман А.Э. и др. Наследственный системный транстиретиновый амилоидоз: клинический случай и мнение по проблеме. Российский кардиологический журнал. 2019; 6: 136–42. DOI: 10.15829/1560-4071-2019-6-136-142 [Draganova A.S., Soboleva A.V., Ertman A.E. et al. Hereditary systemic transthyretin amyloidosis: a clinical case and an opinion on the problem. Rossijskij kardiologicheskij zhurnal. Russian Journal of Cardiology. 2019; 6: 136–42. DOI: 10.15829/1560-4071-2019-6-136- 142 (in Russian).]

3. Рамеева А.С., Рамеев В.В., Моисеев С.В. и др. Амилоидная кардиопатия: патоморфология, методы диагностики и лечения. Consilium Medicum. 2018; 20 (12): 15–22. DOI: 10.26442/20751753. 2018.12.000020 [Rameeva A.S., Rameev V.V., Moiseev S.V. et al. Amyloid heart disease: pathomorphology, diagnostic approaches and treatment options. Consilium Medicum. 2018; 20 (12): 15–22. DOI: 10.26442/ 20751753.2018.12.000020 (in Russian).]

4. Лысенко (Козловская) Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клиническая фармакология и терапия. 2020; 29 (1): 13–24. DOI: 10.32756/0869-5490-2020-1-13-24 [Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev S. et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya. Clin Pharmacol Therapy. 2020; 29 (1): 13–24. DOI: 10.32756/0869-5490-2020-1-13-24 (in Russian).]

5. Maurer MS, Schwartz JH, Gundapaneni B et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379 (11): 1007–16.

6. Siddiqi OK, Ruberg FL. Cardiac Amyloidosis: An Update on Pathophysiology, Diagnosis, and Treatment. Trends in Cardiovasc Med 2018; 28 (1): 10–21. DOI: 10.1016/j. tcm.2017.07.004

7. Bhogal S, Ladia V, Sitwala P et al. Cardiac Amyloidosis: An Updated Review with Emphasis on Diagnosis and Future Directions. Curr Probl Cardiol 2018; 43 (1): 10–34. DOI: 10.1016/j.cpcardiol. 2017.04.003

For citation:Cherkasova N.A., Komarova I.S., Mukhina N.V., Dyatlov N.V. Clinical case of primary generalized amyloidiosis. Clinical review for general practice. 2023; 4 (2): 27–30. DOI: 10.47407/kr2023.4.2.00200

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice